Provided by Tiger Trade Technology Pte. Ltd.

Oric Pharmaceuticals Inc.

10.42
+0.46004.62%
Post-market: 10.420.00000.00%16:50 EST
Volume:1.99M
Turnover:20.67M
Market Cap:1.01B
PE:-6.14
High:10.66
Open:10.43
Low:9.99
Close:9.96
52wk High:14.93
52wk Low:3.90
Shares:97.39M
Float Shares:60.66M
Volume Ratio:1.36
T/O Rate:3.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6957
EPS(LYR):-1.8335
ROE:-39.73%
ROA:-25.23%
PB:2.49
PE(LYR):-5.68

Loading ...

Company Profile

Company Name:
Oric Pharmaceuticals Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
106
Office Location:
240 East Grand Avenue,2nd Floor,South San Francisco,California,United States
Zip Code:
94080
Fax:
- -
Introduction:
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.

Directors

Name
Position
Jacob M. Chacko
President, Chief Executive Officer and Director
Richard Heyman
Chairman and Director
Carl Gordon
Director
Leo Guthart
Director
Mardi Dier
Director
Peter Svennilson
Director
Richard Scheller
Director

Shareholders

Name
Position
Jacob M. Chacko
President, Chief Executive Officer and Director
Dominic Piscitelli
Chief Financial Officer
Pratik Multani
Chief Medical Officer